Detail
| LncRNA Name | ANRIL |
| Synonyms | CDKN2B-AS1, ANRIL, CDKN2B-AS, CDKN2BAS, NCRNA00089, PCAT12, p15AS |
| Region | GRCh38_9:21994778-22121097 Sequence |
| Ensembl | ENSG00000240498 |
| RefSeq | NR_003529 |
| Circulating | ✔ |
| Drug-resisitant | ✘ |
| Prognostic | ✔ |
| MiRNA | ✘ |
| Variant | ✘ |
| TF | ✘ |
| Methylation | ✘ |
| Cancer Name | breast cancer |
| ICD-0-3 | C50 |
| Methods | microarray, qPCR etc. |
| Sample | plasma, breast cancer tissues |
| Expression Pattern | up-regulated |
| Function Description | Expression level of these 3 lncRNAs was determined in plasma samples of 60 patients with BC and 40 healthy individuals by performing real-time PCR. As expected, the relative expression of ANRIL, HIF1A-AS2, and UCA1 was significantly higher in patients with TNBC than in patients with NTNBC, which was consistent with the results of microarray analysis. |
| Pubmed ID | 28248879 |
| Year | 2017 |
| Title | A three-long noncoding RNA signature as a diagnostic biomarker for differentiating between triple-negative and non-triple-negative breast cancers. |
| External Links |
| Links for ANRIL | GenBank HGNC lncrnadb Noncode |
| Links for breast cancer | Omim Cosmic |
CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.